RBCC: NASA Bioreactor Could Speed Parkinson's Research

NOKOMIS, Fla.--(BUSINESS WIRE)--

Stem cell research may hold the key to a cure for Parkinson's disease. The only problem is, stem cell research hasn't advanced as quickly as patients need it to. Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. RBCC is working to market an advanced stem cell growth solution that could potentially energize the worldwide search for a cure.

Currently, government restrictions and ethical dilemmas serve as roadblocks to fast-paced stem cell research, but even when these roadblocks are absent, controlling the behavior of stem cells in a laboratory isn't easy. One way to help speed research projects up and make them more efficient is to raise the number of high-quality adult stem cells available for that research.

RBCC is working to do just that. The company has engaged Regenetech in discussions regarding the potential acquisition of a license to perform cell expansion using that company's Rotary Cell Culture System^TM.

Originally developed by NASA, the Rotary Cell Culture System^TM is a rotating-wall bioreactor designed to facilitate the growth of human cells in simulated weightlessness. Cell cultures, including stem cells, grown inside the bioreactor look and function much closer to human cells grown within the body than the flat cell cultures grown in Petri dishes.

By bringing the bioreactor to emerging research markets where stem cell research faces fewer roadblocks, RBCC hopes to help kickstart billions of dollars worth of research into possible cures for Parkinson's and other neurological disorders.

RBCC plans to offer new technology to compete in the stem-cell research industry alongside Amgen, Inc. AMGN, Celgene Corporation CELG, Genzyme Corp. GENZ and Gilead Sciences Inc. GILD.

For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. RBCC. The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [http://www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.